Skip to main content
Vai all'homepage della Commissione europea (si apre in una nuova finestra)
italiano it
CORDIS - Risultati della ricerca dell’UE
CORDIS

Pre-Comercial Procurement of innovative and sustainable solutions to Treat HEalthcaRE System wAstewater

Descrizione del progetto

Appalto pre-commerciale per la decontaminazione delle acque reflue ospedaliere

Le acque reflue ospedaliere presentano rischi per l’ambiente e la salute. Gli attuali impianti di trattamento non sono in grado di rimuovere tutti gli inquinanti. Ciò significa che le fonti d’acqua contaminate continuano a rappresentare un rischio persistente. Inoltre, le acque reflue ospedaliere ospitano microrganismi resistenti agli antibiotici, contribuendo alla resistenza antimicrobica (AMR), una grave minaccia per la salute. I farmaci ospedalieri specializzati aggravano questo problema. Sebbene esistano diverse tecnologie per il trattamento delle acque reflue ospedaliere, nessuna elimina efficacemente un’ampia gamma di inquinanti. Il progetto THERESA PCP, finanziato dall’UE, avvierà una procedura di appalto pre-commerciale per sviluppare un sistema in loco ecocompatibile per la decontaminazione delle acque reflue ospedaliere. Questo sistema rimuoverà efficacemente contaminanti quali farmaci citostatici, mezzi di contrasto per raggi X, antibiotici e batteri e geni resistenti agli antimicrobici.

Obiettivo

Hospital wastewater (HWW) poses a significant environmental and health risk due to the presence of pharmaceuticals, pathogens, and other hazardous substances that are administered in healthcare institutions. Unfortunately, current urban wastewater treatment (WWT) plants are not capable of effectively removing many of the pollutants generated by hospitals. As a result, these contaminants reach and accumulate in natural water bodies, threatening ecosystems and biodiversity, and public health through the contamination of drinking water or food. In addition, public health is also menaced by HWW as it contains important amounts of antibiotic-resistant microorganisms and genes. In fact, Antimicrobial Resistance (AMR) is one of the greatest health threats of our times.
While most common medicines are consumed in households, specialized drugs such as cytostatic drugs, some antibiotics, or X-ray contrast agents are mainly distributed in hospitals. Furthermore, HWW is a hotspot for the transmission of antibiotic-resistant bacteria (ARB) and antibiotic-resistant genes (ARG). To reduce the risk associated to these contaminants, it is key to remove them as close to their source as possible, and before they are discharged to the municipal water network. Despite the existence of different technologies that efficiently remove contaminants from HWW, currently, there is no single process that can be used for the comprehensive treatment of HWW regarding the elimination of a mix of pollutants to a high degree.
Moreover, technology may be further developed to be more efficient, environmentally sustainable, and cost-effective for hospitals. In this context, the main objective of THERESA PCP is to launch a pre-commercial procurement process (PCP) based on the development of an environmentally sustainable on-site system to decontaminate HWW, being capable of effectively removing, among other contaminants, cytostatic drugs, X-ray contrast agents, antibiotics, ARB and ARG, from HWW.

Campo scientifico (EuroSciVoc)

Parole chiave

Programma(i)

Argomento(i)

Meccanismo di finanziamento

HORIZON-PCP - HORIZON Pre-commercial Procurement

Vedi tutti i progetti finanziati nell’ambito di questo schema di finanziamento

Invito a presentare proposte

(si apre in una nuova finestra) HORIZON-HLTH-2024-CARE-14

Vedi tutti i progetti finanziati nell’ambito del bando

Coordinatore

FUNDACION PUBLICA MIGUEL SERVET
Contributo netto dell'UE
€ 3 352 862,50
Indirizzo
CALLE IRUNLARREA 3 CENTRO INVESTIGACION BIOMEDICA RECINTO COMPLEJO HOSPITALARIO DE NAVARRA
31008 Pamplona
Spagna
Regione
Noreste Comunidad Foral de Navarra Navarra
Tipo di attività
Research Organisations
Collegamenti
Costo totale
€ 3 352 862,50

Partecipanti (16)